2026-10-15T04:59:20Z https://www.scidb.cn/oai

10.57760/sciencedb.36384 2026-02-05T16:44:11Z

2026-02-05 Clinical Outcomes of neoadjuvant immunotherapy in NSCLC in the study doi:10.57760/sciencedb.36384 en This study enrolled 144 stage IB-IIIB NSCLC patients who received neoadjuvant immunotherapy, withpathological response evaluable in 139 patients. The ORR in the cohort was 69.8%. Compared with non-MPR patients, MPR patients exhibited a significantly higher ORR (P = 0.031). However, no significant correlations were observed between ORR and pCR or DFS. (Figure 1A-B). Among evaluable patients, 59 (42.4%) achieved pCR and demonstrated significantly longer DFS versus non-pCR patients (P=0.039, Figure 1C), while 90 (64.7%) attained major pathological response (MPR) without significant DFS improvement (P=0.079, Figure 1D). neoadjuvant immunotherapy; NSCLC; Tumor responses Fang Wu Yurong Peng Yue Zeng Yingzhe Zhang Dan Fan Shuxing Wang Chao Deng Fang Ma Zhenhua Qiu Chen Chen Yan Hu Chunhong Hu Liuwen Liang PUBLIC https://creativecommons.org/licenses/by-nc-nd/4.0/ dataset Science Data Bank